Kenya Class B Registration Routes: Full, Abridged, EBR and IBR
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Content verified as of October 30, 2026
1. Key takeaways
- Class B in Kenya offers four routes: full evaluation (Full), abridged evaluation (Abridged), the expedited route (EBR) and immediate registration (Immediate Class B Registration, IBR).
- Full relies on no prior approval from any reference regulatory agency (RRA) and wins on the completeness of the applicant’s own dossier.
- Abridged requires approvals for the same labeled use from at least 2 RRAs.
- EBR has two gates: at least 2 RRA approvals plus marketing in those jurisdictions for at least 3 years with no safety issues in the past 3 years; or at least 3 RRA approvals.
- IBR has the highest bar: at least 3 RRA approvals plus marketing for at least 4 years in 2 of those jurisdictions, no safety issues in the past 3 years, and never refused or withdrawn.
- Fee baseline: Class B import registration USD 200, annual retention USD 50; expedited review, if added, costs USD 2,000 more.
2. Legal basis
| Instrument | Reference number | Date issued or effective | Provision | Relevance to this article |
|---|---|---|---|---|
| Pharmacy and Poisons Act | Cap. 244, Laws of Kenya | Enacted 1957, as amended | Section 3B(2)(r) | PPB may collaborate with other national, regional and international authorities and recognize and rely on their registrations and certifications while remaining independently responsible for its decisions |
| Guidelines for Registration of Medical Devices including In-Vitro Diagnostics | HPT/PER/HTR/GUD/011, Rev.02 | Effective January 31, 2022; review due January 1, 2027 | Route chapters (Class B: Full/Abridged/EBR/IBR), Section 2.7 | Eligibility conditions of the four routes; timelines run from receipt of the application and exclude clock stops |
| Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022 | Legal Notice No. 100 of 2022 | Made on June 8, 2022 | Second Schedule (Class B registration USD 200.00; expedited review of health products not manufactured in Kenya USD 2,000.00) | Statutory rates corresponding to the routes |
| Guideline for Fast Track Review of Application for Health Products | HPT/PER/GUD/041 | Version currently in force | Full text | Procedural basis for expedited review of Class B and Class C/D products |
3. Expert insights
Insight 1: The four routes form a gradient of reliance, not gears of speed
From Full to IBR, PPB progressively shifts the weight of review from reading the dossier itself to checking whether others have read it. The legal basis is Section 3B(2)(r) of Cap. 244: PPB may recognize and rely on the registrations and certifications of other authorities while remaining independently responsible for its decisions. That sentence produces two consequences for route design. First, reliance is not automatic passage; IBR retains post-registration verification and revocation powers. Second, the further along the gradient, the higher the demand on the internal consistency of the company’s own documents, because what PPB verifies is whether what you state matches the certificates you submit.
Insight 2: The EBR structure built on an OR is the most often misread
The EBR conditions are: at least 2 RRA approvals, marketing for at least 3 years, and no safety issues in the past 3 years; or at least 3 RRA approvals. The second gate imposes no marketing-history requirement, which makes it the most favorable and most overlooked design: a product holding three reference approvals but with less than 3 years on the market can go straight through the second gate. GRZAN sees two kinds of misreading, reading 3 approvals as 3 years and thereby missing EBR, or assuming that two approvals automatically suffice while ignoring the three evidentiary items on safety issues.
Insight 3: No safety issues must be broken into three provable items
The guidelines specify no safety issues as: no reports of death, no reports of serious deterioration in health, and no open field safety corrective action (FSCA, including recalls) at the time of submission. All three can and should be evidenced: the first two come from vigilance database search records, and the third from the closure status of a global FSCA log. The common pitfall is submitting a one-page letter declaring no safety issues. If PPB later verifies that an open recall existed at the submission date, route eligibility is forfeited.
Insight 4: Manage timeline expectations by the clock-stop mechanism, not by a day count
Section 2.7 of the current guidelines states only the principle: the timeline runs from the date the application is received and excludes clock stops caused by input requests, and if the device is undergoing an FSCA the application clock stops until the FSCA is resolved. Specific day counts are not stated in the text of the current guidelines. The first edition of the submission guidelines expressed it as 90 calendar days, with a surcharge of one third of the application fee for failing to respond within 90 calendar days. As a practical estimate, GRZAN advises that project scheduling follow the actual PRIMS clock, and that FSCA status be checked before project initiation, because one open recall can freeze the clock entirely.
4. Practical recommendations
- Count your approvals first. List the RRA approval certificates already held, noting the authority, the scope of approval and the date of first marketing.
- Apply the decision tree in order. Test the three IBR hard gates first, then the two EBR gates, then the two-approval threshold for Abridged; otherwise take Full.
- Evidence no safety issues in three documents. Death-report search, serious-deterioration search and an FSCA closure log, each dated.
- Snapshot route eligibility. Fix the eligibility evidence to the submission date as the reference date to avoid disputes if eligibility shifts during review.
- Screen FSCA status up front. Confirm no open FSCA anywhere before initiation; resolve first, file later.
- Evaluate expedited review separately. If acceleration is genuinely needed, apply under HPT/PER/GUD/041 and budget the USD 2,000.
5. Verification checklist
- □ Have the number and list of RRA approvals held been counted (2 or 3)?
- □ Can marketing-history evidence prove at least 3 years (EBR) or at least 4 years (IBR)?
- □ Do all three no-safety-issue items have traceable evidence?
- □ Is any FSCA, including recalls, open at the time of submission?
- □ Has the intended route been confirmed with a recorded eligibility assessment?
- □ Have the necessity of expedited review and the USD 2,000 fee been evaluated?
- □ Does the labeled use of the reference approvals match the intended market use?
- □ Is scheduling managed by the clock-stop mechanism rather than by applying 90 calendar days directly (practical estimate)?
Regulatory information verified as of October 30, 2026.
Across African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt, and operates a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally rests solely on official gazettes, the original text of competent authority guidelines and public legal databases, each marked with its verification date. Any figure, timeline or amount that cannot be located in an official source is labeled as a practical estimate and never presented as an assumption.
GRZAN services cover market access strategy and risk classification assessment; preparation and review of registration dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; and regulatory intelligence subscription with corporate compliance record-keeping.
For a Kenya market access plan tailored to your specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us